Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy

Table 1 Role of cannabinoid agents in diabetes

Cannabinoid agent	Mechanism	Role in diabetes
Anandamide	Endogenous cannabinoid	Elevated in diabetic patients[26]
	CB1 agonist
	CB2 agonist
Rimonabant (SR141716A)	CB1 antagonist	Reduced weight[62]
		Reduced hemoglobin A1c levels[62]
		Reduced fasting blood glucose levels[62]
		Reduced high density lipoprotein, cholesterol and triglyceride levels[62]
		Improved systolic blood pressure[62]
Δ9-tetrahydrocannabinol (THC)	Psychoactive cannabinoid	Lowered blood glucose level[65]; Preserved pancreatic insulin content[65]
	CB1 partial agonist
	CB2 partial agonist
Cannabidiol	Non-psychoactive cannabinoid	Reduced the incidence of type I diabetes[66]
	Low affinity to CB1 and CB2	Immunosuppressive effect[66]